<DOC>
	<DOCNO>NCT00003198</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy ifosfamide topotecan treating patient refractory solid tumor .</brief_summary>
	<brief_title>Ifosfamide Topotecan Treating Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dos sequence topotecan ifosfamide administer daily 3 day every 4 week schedule patient refractory solid tumor . II . Evaluate toxicity topotecan ifosfamide administer schedule patient population . III . Evaluate pharmacokinetics related sequence topotecan ifosfamide efficacious , less toxic schedule treatment . IV . Assess evidence antineoplastic activity combination agent . OUTLINE : This open label , dose escalation study . Cohorts 3-6 patient receive ifosfamide initial fix dose plus escalating dos topotecan 30 minute infusion daily 3 successive day . Cycle repeat every 28 day . After topotecan dosage escalate total 3 dose level , ifosfamide dose escalated one dose level . The first patient enrol treat ifosfamide follow topotecan cycle 1 , cycle 2 order drug reverse . The second patient treat drug topotecan administer ifosfamide first cycle reverse second cycle . From third cycle onward , ifosfamide follow topotecan , first two cycle continue alternate subsequent patient enter . Filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) give cycle day 5-12 absolute granulocyte count reach nadir recover . If dose limit toxicity ( DLT ) cohort , new patient enter next high dose level . If 1 3 patient level experience DLT , additional 3 patient treated level proceed high level . If 2 patient experience DLT dose level , level immediately precede level define maximum tolerated dose ( MTD ) . Three patient treat MTD ensure DLT experienced level . After MTD identify , 10 additional patient accrue level . Patients minor response , stable disease , symptomatic marker improvement may continue treatment 6 cycle . After 6 cycle , continuation treatment investigator 's discretion . PROJECTED ACCRUAL : There maximum 24 patient accrue study 8 month .</detailed_description>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor Refractory disease ; curable surgery , radiation therapy , standard chemotherapy Measurable evaluable disease require evidence radiographic abnormality , abnormal physical exam , elevate tumor marker least 3 time normal No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.8 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : No medical psychiatric condition Not pregnant Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior topotecan ifosfamide At least 4 week since myelosuppressive chemotherapy At least 6 week since nitrosourea mitomycin Must recover prior therapy Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy pelvis At least 4 week since radiation therapy major bone marrow contain area Surgery : Must option surgery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>